StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012

NEWARK, Calif., Feb. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM - News) today announced that it will participate in the Qatar International Conference on Stem Cell Science and Policy, which is being held in Qatar from February 27 to March 1, 2012. The Company, which is the leader in development of cell-based therapeutics for central nervous system disorders, was specifically invited by the conference's sponsors, the State of Qatar and Amir of Qatar His Highness Sheikh Hamad bin Khalifa Al-Thani, as well as the James A. Baker III Institute for Public Policy of Rice University, and is the only company to be invited.

Ann Tsukamoto, Ph.D., StemCells' Executive Vice President, Research and Development, will make a presentation on the clinical translation of human neural stem cells. StemCells was the first company to receive authorization from the US Food and Drug Administration to conduct a clinical trial of purified human neural stem cells, and the Company is currently conducting two clinical trials with a third anticipated to start later this year. Dr. Tsukamoto will also be the moderator of the panel session on neurological disorders, which is scheduled to be held on March 1 from 9:30 a.m. to 11:00 a.m. Arabian Standard Time (AST).

In addition, Irving Weissman, M.D., Chairman of StemCells' Scientific Advisory Board, will make a keynote presentation to the conference on Tuesday, February 28 at 9:00 a.m. AST. Dr. Weissman, who is Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at the Stanford School of Medicine, and Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine, will speak on normal and neoplastic stem cells. Dr. Weissman will also participate in a panel discussion on the opportunities and challenges for stem cell research, and will moderate a panel discussion on pluripotent stem cells.

The Qatar International Conference on Stem Cell Science and Policy will bring together more than 400 international participants from industry, academia and public policy, including leading experts from each of these sectors. The conference's objectives are to showcase the latest stem cell research from around the world, while promoting discussion and awareness of scientific, ethical and regulatory issues related to this innovative and dynamic field.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. The Company recently completed a clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, and expects to report the trial results soon. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury, and expects to initiate a Phase I/II clinical trial in dry age- related macular degeneration in the near future. In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Form 10-Q and Form 8-K.

See the rest here:
StemCells, Inc. to Participate in Qatar International Conference on Stem Cell Science and Policy 2012